SCHEMBL435772

SCHEMBL435772

NC(=O)CCCC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2077059 0.92
SCHEMBL6056944 0.89 FAAH (0.56)
SCHEMBL16915252 0.89 FAAH (0.56)
SCHEMBL8812772 0.89 FAAH (0.56)
SCHEMBL5126817 0.89 FAAH (0.56)
SCHEMBL25335744 0.89 FAAH (0.56)
SCHEMBL8812335 0.89 FAAH (0.56)
SCHEMBL12655381 0.89 FAAH (0.56)
SCHEMBL1365131 0.89 FAAH (0.56)
SCHEMBL5127507 0.89 FAAH (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110240629-B Protein degradation targeting BCR-ABL compound and antitumor application thereof 上海科技大学 2023-10-03 CN claimed
EP-4735452-A2 HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN Merck Patent GmbH (DE) 2026-05-06 EP disclosed
EP-4631952-A1 GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-10-15 EP disclosed
CN-119462518-A Double-target conjugate synthesized based on PARP1 inhibitor and Rigosertib, and preparation method and application thereof 淮阴工学院 2025-02-18 CN disclosed
WO-2025006753-A2 HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN MERCK PATENT GMBH (DE) 2025-01-02 WO disclosed
WO-2024256569-A1 NOVEL CDK DEGRADERS RIJKSUNIVERSITEIT GRONINGEN (NL) 2024-12-19 WO disclosed
CN-116375713-B DCLK1 protein degradation targeting chimeric and application thereof 中国人民解放军海军军医大学 2024-11-19 CN disclosed
WO-2024230301-A1 ANTIBODY-CONJUGATED DRUG AND USE THEREOF 诺灵生物医药科技(北京)有限公司 2024-11-14 WO disclosed
CN-118924912-A Antibody coupling medicine and application thereof 诺灵生物医药科技(北京)有限公司 2024-11-12 CN disclosed
CN-113412271-B Having cysteine residues Hamiltelin derivatives of (C) 住友制药株式会社 2024-10-22 CN disclosed
CN-1181069-A 5 -(4 -subst. -piperidinyl -1) -3 -aryl -pentanoic acid derivatives as tachykinin receptor antagonist ZENECA LTD (GB) 1998-05-06 CN disclosed
EP-0832618-A1 Stent for dilating a stenotic lesion of a blood vessel TERUMO KABUSHIKI KAISHA (JP) 1998-04-01 EP disclosed
US-5707937-A AGRICULTURAL HERBICIDES, DESICCANTS, DEFOLIANTS, HARVESTING AIDS BASF AKTIENGESELLSCHAFT (DE) 1998-01-13 US disclosed
US-5674829-A CONSISTS OF GLUTARALDEHYDE, NONYL PHENYL ETHOXYLATE NONIONIC DETERGENT, SODIUM ACETATE TRIHYDRATE BUFFER AND SODIUM HYDROXIDE PH MODIFIER; USEFUL FOR DISINFECTING AND CLEANING Martin, Antoinetta P. (ZA) 1997-10-07 US disclosed
WO-1996014298-A1 SUBSTITUTED PHTHALIMIDO-CINNAMIC ACID DERIVATIVES WITH HERBICIDAL EFFECT BASF AKTIENGESELLSCHAFT (DE) 1996-05-17 WO disclosed
CN-1100135-A A glutaraldehyde composition TONI MARTIN MARKETING AND DIST (ZA) 1995-03-15 CN disclosed
EP-0609106-A1 A glutaraldehyde composition TONI MARTIN MARKETING AND DISTRIBUTORS CC (ZA) 1994-08-03 EP disclosed
EP-0175187-B1 3,4-DIHYDRO-2(1H)-PYRIDONES AND 2(1H)-PYRIDONES CONTAINING IMIDAZOLE GROUPS, METHOD FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1990-01-10 EP disclosed
US-4699914-A CONGESTIVE HEART FAILURE A. NATTERMANN & CIE GMBH (DE) 1987-10-13 US disclosed
EP-0175187-A1 3,4-Dihydro-2(1H)-pyridones and 2(1H)-pyridones containing imidazole groups, method for their preparation and medicaments containing them A. Nattermann & Cie. GmbH (DE) 1986-03-26 EP disclosed